The independent medical news service

Adding low-dose or hypofractionated radiotherapy to durvalumab plus tremelimumab offers no significant benefit to people with non-small-cell lung cancer that is resistant to PD-1 or PD-L1 inhibition, US study findings indicate.

Cutaneous immune-related adverse events are associated with a reduced risk for death among cancer patients with immune checkpoint inhibitors, research suggests.

The PD-L1 inhibitor sugemalimab has shown potential both as a consolidation treatment option for inoperable, locally advanced non-small-cell lung cancer as well as in combination with chemotherapy for the first-line treatment of metastatic disease.

Treatment with immune checkpoint inhibitors within 90 days of radiotherapy does not lead to a “meaningful increase” in rates of serious adverse events, say researchers who conducted a pooled analysis of US FDA registry data.

A post-hoc analysis of a randomized trial points to the benefit of adding metformin to an EGFR–tyrosine kinase inhibitor in advanced non-small-cell lung cancer patients with a BMI of at least 24 kg/m².

Quitting smoking around the time of receiving a lung cancer diagnosis is associated with significantly improved overall survival than continuing smoking, shows a meta-analysis published in the Journal of Thoracic Oncology.

Treatment-naïve patients with advanced squamous non-small-cell lung cancer derive a significant progression-free survival and overall survival benefit with the addition of camrelizumab to chemotherapy, indicates the Chinese CameL-sq study.

Click through for more information

Click through for more information about these non-small-cell lung cancer opinions

The risk for disease progression or death increases with HLA-A*03 allele count in people undergoing immune checkpoint inhibitor therapy for cancer, irrespective of tumor type and agent used, research suggests.

Vibostolimab given alone or in combination with pembrolizumab is well tolerated and demonstrates antitumor activity in patients with advanced solid tumors, including non-small-cell lung cancer, show results of a first-in-human study of the antibody targeting the TIGIT domain. 

The tyrosine kinase inhibitor poziotinib has antitumor activity in heavily pretreated patients with advanced or metastatic non-small-cell lung cancer harboring HER2 exon 20 insertions, show data from the phase 2 ZENITH20 trial.

Click through for further information on this announcement

People with EGFR-positive non-small-cell lung cancer may benefit from individualized risk-profiling, say researchers who observed a high recurrence risk following resection but also identified a subgroup that may be cured without adjuvant osimertinib.

Incorporating geriatric assessment-guided management into the care of older patients receiving anticancer therapy could reduce the risk for treatment toxicity and falls as well as polypharmacy, suggests a cluster randomized controlled trial.

Age alone should not preclude the use of immune checkpoint inhibitors in people with cancer aged 80 years or more, say researchers who found promising efficacy and tolerability of single-agent therapy in this patient population.

A high proportion of individuals with non-small-cell lung cancer who complete 2 years of immune checkpoint inhibitor treatment show durable responses after stopping treatment, show real-world data from Korea.

Read more about these clinical practice guidelines here

A large single-center study has found an association between immune checkpoint inhibitor use and an increased incidence of venous thromboembolism in people with cancer.

A geriatric assessment-driven intervention may reduce the risk for grade 3 or higher chemotherapy-related toxicities in older people with cancer, research suggests.